Schedule 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. n/a )*

HemoBioTech, Inc.

(Name of Issuer)

Common Stock, $0.001 Par Value Per Share

(Title of Class of Securities)

42368P102

(CUSIP Number)

December 31, 2009

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

o Rule 13d-1(c)

x Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.

42368P102

< TD align="left" colSpan="4">7.68%


1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Bollon Arthur

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a) o
	(b) o

3	SEC USE ONLY



4	CITIZENSHIP OR PLACE OF ORGANIZATION

	United States of America

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:		5	SOLE VOTING POWER

			1,605,394 Shares

		6	SHARED VOTING POWER

			217,223 Shares

		7	SOLE DISPOSITIVE POWER

			1,605,394 Shares

		8	SHARED DISPOSITIVE POWER

			217,223 Shares

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

	1,822,617

10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

	o

11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)



12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

	IN
	FOOTNOTES

	(1) Represents (a) 1,381,836 shares of common stock owned by Dr. Bollon; (b) 217,223 shares of common stock directly beneficially owned by Biogress LLC, of which Dr. Bollon is a founding member and has 50% voting pwoer; (c) options to purchase 80,558 shares of common stock directly beneficially owned by Dr. Bollon which vest within 60 days of the date hereof and; (d) options to purchase 143,0000 shares of common stock directly beneficially owned by Dr.Bollon all of which are fully vested and immediately exercisable.

Item 1.

(a)

Name of Issuer

HemoBioTech, Inc.

(b)

Address of Issuer’s Principal Executive Offices

5001 Spring Valley Rd, Ste 1040 -West, Dallas, TX 75244

Item 2.

(a)

Name of Person Filing

Dr. Arthur Bollon

(b)

Address of Principal Business Office or, if none, Residence

c/o 5001 Spring Valley Rd, Ste 1040-West, Dallas, TX 75244

(c)

Citizenship

Dr. Bollon is a citizen of United States of America

(d)

Title of Class of Securities

Common Stock, $0.001 Par Value Per Share

(e)

CUSIP Number

42368P102

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. o78c).

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

(e)

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4.

Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount beneficially owned: 1,822,617

(b)

Percent of class: 7.68

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: 1,605,394

(ii)

Shared power to vote or to direct the vote: 217,223

(iii)

Sole power to dispose or to direct the disposition of: 1,605,394

(iv)

Shared power to dispose or to direct the disposition of: 217,223

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .

Not Applicable

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable

Item 8.

Identification and Classification of Members of the Group

None of the reporting persons who have filed this schedule is a person, as defined in Rule 13d-1(b)(1)(ii), promulgated pursuant to the Securities Act of 1934

Item 9.

Notice of Dissolution of Group

Not Applicable

Item 10.	Certification

	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.



Date: February 16, 2010	By:	/s/ Arthur Bollon
		Name: Arthur Bollon
		Title: Arthur Bollon

Footnotes:

Attention:

Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)